Physician profile
Robert D Broderick
NPI 1275537656
$1,624.96
in general payments reported to CMS, 2019-2025
20 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $51.82 · 2021: $162 · 2022: $210 · 2023: $328 · 2024: $423 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $228.12 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $189.24 | 2022-2023 | Miebo, Xipere, Visudyne |
| Oyster Point Pharma, INC. | $150.54 | 2022-2025 | Tyrvaya |
| Abbvie INC. | $145.17 | 2022-2025 | Alphagan P, Lumigan |
| Tarsus Pharmaceuticals, INC. | $145.03 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $120.40 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $97.31 | 2021-2022 | |
| Harrow Eye, LLC | $97.12 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $96.89 | 2019-2021 | |
| Thea Pharma INC. | $63.43 | 2022-2025 | Iyuzeh |
| Alcon Vision LLC | $49.55 | 2023 | Hydrus Microstent, Simbrinza |
| Genentech USA, INC. | $43.67 | 2024 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $38.66 | 2020-2022 | |
| Dompe US, INC. | $32.87 | 2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $31.47 | 2025 | Purified Cortrophin Gel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $22.59 | 2021 | |
| Ocular Therapeutix, INC. | $19.83 | 2023 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.70 | 2020 | |
| Eyevance Pharmaceuticals LLC | $18.50 | 2022 | |
| Allergan, INC. | $15.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Broderick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.